ORXOF (Orexo AB) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jun. 24, 2026)


ORXOF Orexo AB ORXOF
34 GF Score
Price $2.10
GF Value $0.68
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Float Percentage Of Total Shares Outstanding?

Orexo AB ORXOF 34 Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 24, 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orexo AB's float shares is 0.00 Mil. Orexo AB's total shares outstanding is 35.13 Mil. Orexo AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orexo AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orexo AB's Institutional Ownership is 2.32%.

ORXOF
34GF Score
Orexo AB ORXOF
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Orexo AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/35.13
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Orexo AB (ORXOF) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jun. 24, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Orexo AB and its competitors.
Is Orexo AB's Float Percentage Of Total Shares Outstanding too high?
Orexo AB's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Float Percentage Of Total Shares Outstanding compare to ZTS?
Orexo AB's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Orexo AB and its competitors. Orexo AB's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOF) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOF:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score

Get the complete analysis for ORXOF

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$0.68
GF Value